Systematic review: interferon-free regimens for patients with HCV-related Child C cirrhosis

M. Guarino, F. Morisco, M. R. Valvano, A. M. Ippolito, M. Librandi, N. Andriulli, M. Greco, A. Amoruso, A. Iacobellis, G. Niro, N. Caporaso, A. Andriulli

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

Background: It is unclear whether the efficacy and long-term outcome of treating patients with hepatitis C virus (HCV)-positive cirrhosis with the new protease inhibitors will extend to those with Child C cirrhosis. Aim: To assess the effectiveness of the interferon-free regimens in Child C cirrhotic patients with HCV infection. Methods: A systematic Medline search was conducted to retrieve studies describing the treatment of Child C patients with direct-acting agents. Citations from identified studies were cross-referenced and abstracts from European Association for the Study of the Liver (EASL) and American Association for the Study of Liver Disease (AASLD) meetings were checked. Extracted data were evaluated using a meta-analysis to calculate a weighted response rate. Results: Seven full-text records and two conference abstracts were retained for analysis from the 649 records identified. Data from an Italian real-life trial were also interrogated. Information on treatment outcome was available for 228 of the 240 Child C patients evaluated in the 10 trials. Overall, the weighted mean sustained virological response (SVR12) was 74.9% (95% CI: 65.6–82.4%). Neither duration of treatment (24 or 12 weeks), nor addition of ribavirin influenced these rates. The weighted SVR12 was 65.4% (95% CI: 46.8–80.2) after sofosbuvir/simeprevir, 76.0% (95% CI: 54.4–89.3%) after sofosbuvir/daclatasvir and 83.0% (95% CI: 73.4–89.6) after sofosbuvir/ledipasvir. Some studies did not provide information on the rate of post-treatment relapse or functional improvement. However, in those studies that did provide such data, a relapse was documented in 12.1% of patients and an improvement of ≥2 points on the model for end-stage liver disease (MELD) score in 61.1% of patients. Conclusion: The improvement in MELD scores strongly suggests HCV-positive patients with Child C cirrhosis should be treated with these agents.

Original languageEnglish
Pages (from-to)1193-1200
Number of pages8
JournalAlimentary Pharmacology and Therapeutics
Volume45
Issue number9
DOIs
Publication statusPublished - May 1 2017

Fingerprint

Hepacivirus
Interferons
Fibrosis
End Stage Liver Disease
Recurrence
Ribavirin
Virus Diseases
Protease Inhibitors
Meta-Analysis
Liver Diseases
Therapeutics

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Systematic review : interferon-free regimens for patients with HCV-related Child C cirrhosis. / Guarino, M.; Morisco, F.; Valvano, M. R.; Ippolito, A. M.; Librandi, M.; Andriulli, N.; Greco, M.; Amoruso, A.; Iacobellis, A.; Niro, G.; Caporaso, N.; Andriulli, A.

In: Alimentary Pharmacology and Therapeutics, Vol. 45, No. 9, 01.05.2017, p. 1193-1200.

Research output: Contribution to journalReview article

Guarino, M, Morisco, F, Valvano, MR, Ippolito, AM, Librandi, M, Andriulli, N, Greco, M, Amoruso, A, Iacobellis, A, Niro, G, Caporaso, N & Andriulli, A 2017, 'Systematic review: interferon-free regimens for patients with HCV-related Child C cirrhosis', Alimentary Pharmacology and Therapeutics, vol. 45, no. 9, pp. 1193-1200. https://doi.org/10.1111/apt.14017
Guarino, M. ; Morisco, F. ; Valvano, M. R. ; Ippolito, A. M. ; Librandi, M. ; Andriulli, N. ; Greco, M. ; Amoruso, A. ; Iacobellis, A. ; Niro, G. ; Caporaso, N. ; Andriulli, A. / Systematic review : interferon-free regimens for patients with HCV-related Child C cirrhosis. In: Alimentary Pharmacology and Therapeutics. 2017 ; Vol. 45, No. 9. pp. 1193-1200.
@article{f602f66622274e91b68df17f90357bc9,
title = "Systematic review: interferon-free regimens for patients with HCV-related Child C cirrhosis",
abstract = "Background: It is unclear whether the efficacy and long-term outcome of treating patients with hepatitis C virus (HCV)-positive cirrhosis with the new protease inhibitors will extend to those with Child C cirrhosis. Aim: To assess the effectiveness of the interferon-free regimens in Child C cirrhotic patients with HCV infection. Methods: A systematic Medline search was conducted to retrieve studies describing the treatment of Child C patients with direct-acting agents. Citations from identified studies were cross-referenced and abstracts from European Association for the Study of the Liver (EASL) and American Association for the Study of Liver Disease (AASLD) meetings were checked. Extracted data were evaluated using a meta-analysis to calculate a weighted response rate. Results: Seven full-text records and two conference abstracts were retained for analysis from the 649 records identified. Data from an Italian real-life trial were also interrogated. Information on treatment outcome was available for 228 of the 240 Child C patients evaluated in the 10 trials. Overall, the weighted mean sustained virological response (SVR12) was 74.9{\%} (95{\%} CI: 65.6–82.4{\%}). Neither duration of treatment (24 or 12 weeks), nor addition of ribavirin influenced these rates. The weighted SVR12 was 65.4{\%} (95{\%} CI: 46.8–80.2) after sofosbuvir/simeprevir, 76.0{\%} (95{\%} CI: 54.4–89.3{\%}) after sofosbuvir/daclatasvir and 83.0{\%} (95{\%} CI: 73.4–89.6) after sofosbuvir/ledipasvir. Some studies did not provide information on the rate of post-treatment relapse or functional improvement. However, in those studies that did provide such data, a relapse was documented in 12.1{\%} of patients and an improvement of ≥2 points on the model for end-stage liver disease (MELD) score in 61.1{\%} of patients. Conclusion: The improvement in MELD scores strongly suggests HCV-positive patients with Child C cirrhosis should be treated with these agents.",
author = "M. Guarino and F. Morisco and Valvano, {M. R.} and Ippolito, {A. M.} and M. Librandi and N. Andriulli and M. Greco and A. Amoruso and A. Iacobellis and G. Niro and N. Caporaso and A. Andriulli",
year = "2017",
month = "5",
day = "1",
doi = "10.1111/apt.14017",
language = "English",
volume = "45",
pages = "1193--1200",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "9",

}

TY - JOUR

T1 - Systematic review

T2 - interferon-free regimens for patients with HCV-related Child C cirrhosis

AU - Guarino, M.

AU - Morisco, F.

AU - Valvano, M. R.

AU - Ippolito, A. M.

AU - Librandi, M.

AU - Andriulli, N.

AU - Greco, M.

AU - Amoruso, A.

AU - Iacobellis, A.

AU - Niro, G.

AU - Caporaso, N.

AU - Andriulli, A.

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Background: It is unclear whether the efficacy and long-term outcome of treating patients with hepatitis C virus (HCV)-positive cirrhosis with the new protease inhibitors will extend to those with Child C cirrhosis. Aim: To assess the effectiveness of the interferon-free regimens in Child C cirrhotic patients with HCV infection. Methods: A systematic Medline search was conducted to retrieve studies describing the treatment of Child C patients with direct-acting agents. Citations from identified studies were cross-referenced and abstracts from European Association for the Study of the Liver (EASL) and American Association for the Study of Liver Disease (AASLD) meetings were checked. Extracted data were evaluated using a meta-analysis to calculate a weighted response rate. Results: Seven full-text records and two conference abstracts were retained for analysis from the 649 records identified. Data from an Italian real-life trial were also interrogated. Information on treatment outcome was available for 228 of the 240 Child C patients evaluated in the 10 trials. Overall, the weighted mean sustained virological response (SVR12) was 74.9% (95% CI: 65.6–82.4%). Neither duration of treatment (24 or 12 weeks), nor addition of ribavirin influenced these rates. The weighted SVR12 was 65.4% (95% CI: 46.8–80.2) after sofosbuvir/simeprevir, 76.0% (95% CI: 54.4–89.3%) after sofosbuvir/daclatasvir and 83.0% (95% CI: 73.4–89.6) after sofosbuvir/ledipasvir. Some studies did not provide information on the rate of post-treatment relapse or functional improvement. However, in those studies that did provide such data, a relapse was documented in 12.1% of patients and an improvement of ≥2 points on the model for end-stage liver disease (MELD) score in 61.1% of patients. Conclusion: The improvement in MELD scores strongly suggests HCV-positive patients with Child C cirrhosis should be treated with these agents.

AB - Background: It is unclear whether the efficacy and long-term outcome of treating patients with hepatitis C virus (HCV)-positive cirrhosis with the new protease inhibitors will extend to those with Child C cirrhosis. Aim: To assess the effectiveness of the interferon-free regimens in Child C cirrhotic patients with HCV infection. Methods: A systematic Medline search was conducted to retrieve studies describing the treatment of Child C patients with direct-acting agents. Citations from identified studies were cross-referenced and abstracts from European Association for the Study of the Liver (EASL) and American Association for the Study of Liver Disease (AASLD) meetings were checked. Extracted data were evaluated using a meta-analysis to calculate a weighted response rate. Results: Seven full-text records and two conference abstracts were retained for analysis from the 649 records identified. Data from an Italian real-life trial were also interrogated. Information on treatment outcome was available for 228 of the 240 Child C patients evaluated in the 10 trials. Overall, the weighted mean sustained virological response (SVR12) was 74.9% (95% CI: 65.6–82.4%). Neither duration of treatment (24 or 12 weeks), nor addition of ribavirin influenced these rates. The weighted SVR12 was 65.4% (95% CI: 46.8–80.2) after sofosbuvir/simeprevir, 76.0% (95% CI: 54.4–89.3%) after sofosbuvir/daclatasvir and 83.0% (95% CI: 73.4–89.6) after sofosbuvir/ledipasvir. Some studies did not provide information on the rate of post-treatment relapse or functional improvement. However, in those studies that did provide such data, a relapse was documented in 12.1% of patients and an improvement of ≥2 points on the model for end-stage liver disease (MELD) score in 61.1% of patients. Conclusion: The improvement in MELD scores strongly suggests HCV-positive patients with Child C cirrhosis should be treated with these agents.

UR - http://www.scopus.com/inward/record.url?scp=85014442113&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014442113&partnerID=8YFLogxK

U2 - 10.1111/apt.14017

DO - 10.1111/apt.14017

M3 - Review article

C2 - 28261822

AN - SCOPUS:85014442113

VL - 45

SP - 1193

EP - 1200

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 9

ER -